Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults

Inclusion Criteria: male and female children of 6 to less than 12 years of age, adolescents of 12 to less than 18 years of age and adults from 18 years: * scheduled for first cytotoxic chemotherapy cycle because of hematologic malignancies * and at intermediate or high risk of TLS * and with no access to rasburicase Exclusion Criteria: * patients with contraindications as per febuxostat summary of product characteristics * patients with severe renal insufficiency * patients with severe hepatic insufficiency * patients with diagnosis of Laboratory TLS (LTLS) or Clinical TLS (CTLS)